247 results on '"Gillard, Michel"'
Search Results
2. Humanized zebrafish as a tractable tool for in vivo evaluation of pro-myelinating drugs
3. Structural Monitoring of an Aerial Tramway System During Operation: Modeling and Simulation Strategy with Experimental Data Validation
4. Discovery of novel compounds and target mechanisms using a high throughput, multiparametric phenotypic screen in a human neuronal model of Tuberous Sclerosis
5. Repurposing HAMI3379 to Block GPR17 and Promote Rodent and Human Oligodendrocyte Differentiation
6. Structures of synaptic vesicle protein 2A and 2B bound to anticonvulsants
7. [11C]UCB-A, a novel PET tracer for synaptic vesicle protein 2 A
8. Development of an HTRF Assay for the Detection and Characterization of Inhibitors of Catechol-O-Methyltransferase
9. Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond
10. The tau positron‐emission tomography tracer AV‐1451 binds with similar affinities to tau fibrils and monoamine oxidases
11. Connectivity Mapping Using a Novel sv2a Loss-of-Function Zebrafish Epilepsy Model as a Powerful Strategy for Anti-epileptic Drug Discovery
12. Characterization of P2X4 receptor agonists and antagonists by calcium influx and radioligand binding studies
13. Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein
14. Evaluating Diagnostic Accuracy of Saliva Sampling Methods for Severe Acute Respiratory Syndrome Coronavirus 2 Reveals Differential Sensitivity and Association with Viral Load
15. Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment
16. Rotigotine is a potent agonist at dopamine D1 receptors as well as at dopamine D2 and D3 receptors
17. A Flow-Through Fluorescence Polarization Detection System for Measuring GPCR-Mediated Modulation of cAMP Production
18. Evaluation of saliva sampling procedures for SARS-CoV-2 diagnostics reveals differential sensitivity and association with viral load
19. Targeting SV2A for Discovery of Antiepileptic Drugs
20. Drug Binding Assays do not Reveal Specific Binding of Lacosamide to Collapsin Response Mediator Protein 2 (CRMP-2)
21. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: Relationship to anti-convulsant properties
22. Targeting SV2A for discovery of antiepileptic drugs
23. Pharmacological Profile of the Novel Antiepileptic Drug Candidate Padsevonil: Interactions with Synaptic Vesicle 2 Proteins and the GABAA Receptor
24. Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam
25. SV2A protein is a broad-spectrum anticonvulsant target: Functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy
26. Relevance of H1-receptor occupancy to H1-antihistamine dosing in children
27. Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein
28. Changes in pH differently affect the binding properties of histamine H1 receptor antagonists
29. Characterization of [3H]ucb 30889 binding to synaptic vesicle protein 2A in the rat spinal cord
30. [3H]linopirdine binding to rat brain membranes is not relevant for M-channel interaction
31. Mutational analysis of the histamine H1-receptor binding pocket of histaprodifens
32. Localization and photoaffinity labelling of the levetiracetam binding site in rat brain and certain cell lines
33. Binding characteristics of [3H]ucb 30889 to levetiracetam binding sites in rat brain
34. Histamine H1 receptor antagonism by cetirizine in isolated guinea pig tissues: influence of receptor reserve and dissociation kinetics
35. Further evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein
36. 5-HT7Receptor Antagonists with an Unprecedented Selectivity Profile
37. The tau positron‐emission tomography tracer AV‐1451 binds with similar affinities to tau fibrils and monoamine oxidases
38. The Orphan Receptor GPR17 Is Unresponsive to Uracil Nucleotides and Cysteinyl Leukotrienes
39. Концепция замещения рецепторов как предиктор клинической эффективности препарата: сравнительный анализ блокаторов Н1-рецепторов второго поколения
40. Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein
41. Evidence for a Differential Interaction of Brivaracetam and Levetiracetam with the SV2A Protein (P5.246)
42. The Orphan G Protein-coupled Receptor GPR17 Negatively Regulates Oligodendrocyte Differentiation via Gαi/o and Its Downstream Effector Molecules
43. In Vitro and In Vivo Identification of Novel Positive Allosteric Modulators of the Human Dopamine D2 and D3 Receptor
44. 5‐HT7 Receptor Antagonists with an Unprecedented Selectivity Profile.
45. O4‐07‐01: T807, a reported selective tau tracer, binds with nanomolar affinity to monoamine oxidase a
46. Rotigotine is a potent agonist at dopamine D1receptors as well as at dopamine D2and D3receptors
47. Evaluation of 18F-UCB-H as a Novel PET Tracer for Synaptic Vesicle Protein 2A in the Brain
48. 5:00 PM NEGATIVE MODULATION OF THE SYNAPTIC VESICLE PROTEIN (SV2A): A NEW PHARMACOLOGICAL TARGET FOR COGNITIVE DEFICIT ASSOCIATED WITH SCHIZOPHRENIA
49. Development of [3H]2-Carboxy-4,6-dichloro-1H-indole-3-propionic Acid ([3H]PSB-12150): A Useful Tool for Studying GPR17
50. Decoding Signaling and Function of the Orphan G Protein–Coupled Receptor GPR17 with a Small-Molecule Agonist
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.